Kevin Kinsella

Kevin Kinsella founded Avalon Ventures in 1983 and built it into one of the longest-running early-stage venture firms on the West Coast. Over his career he has specialized in the formation, financing, and development of more than 125 early-stage companies, frequently acting as the founding chairman rather than a passive investor. He served as founding chairman of Athena Neurosciences, Aurora Biosciences, Landmark Graphics, NeoRx, Onyx Pharmaceuticals, Synaptics, Vertex Pharmaceuticals, X-Ceptor, and Sequana Therapeutics — a portfolio that produced multiple public offerings and multi-billion-dollar drugs for cancer, rheumatoid arthritis, and cystic fibrosis, as well as the touch-screen technology behind the Apple iPhone. Avalon (based in La Jolla) has deployed more than $750 million into early-stage life-science and technology companies, many with roots in the San Diego area.

Kinsella holds a Bachelor of Science in management (with minors in electrical engineering and political science) from MIT, a Master of Arts in international relations from the Johns Hopkins School of Advanced International Studies (SAIS), and did post-graduate work in political economy on a Rotary International Fellowship at the University of Stockholm, Sweden. His pre-venture career was unusually eclectic: he directed international joint ventures, barter, and counter-trade at Solar Turbines International (a Caterpillar Tractor subsidiary), advised the Peruvian government on national nutrition planning (developing a commercialization strategy for quinoa), ran a U.S.–Latin America technology exchange program out of Mexico City, and taught algebra at the American High School in Beirut, Lebanon.

Outside venture capital, Kinsella is a notable Broadway producer, winning the 2006 Tony Award for the mega-hit musical *Jersey Boys* and earning a 2012 Tony nomination for *Jesus Christ Superstar*; he also partnered with Rhino Records on the Grammy-winning, double-platinum *Jersey Boys* cast recording. He is a member of the Council on Foreign Relations and the Circumnavigators Club, and owns Kinsella Estates Winery in Healdsburg, California, whose Dry Creek Valley cabernet has earned 95- and 96-point ratings from Wine Advocate and Wine Spectator.

In recent years Avalon's dedicated life-sciences activity has been organized under Avalon BioVentures, a $135 million fund raised in 2022 focused exclusively on early-stage life-science and biotechnology startups, with managing partner Sandy Madigan leading that vehicle while Kinsella remains the firm's founder.

• Invests at the seed / earliest stage, often *forming* companies rather than joining existing rounds — a company-builder model where Avalon is founding chairman and first money in.
• Sector split: deep biotech/life sciences and information technology; the firm has repeatedly built platform companies in both.
• Prizes original ideas over pattern-matching: "When you think about really successful companies, they are not repeating something other successful companies have done." He explicitly refuses to invest by looking backward at what already worked.
• Blends analytical rigor with gut and conviction — he backed *Jersey Boys* after attending a single rehearsal, and describes similar instinct-driven conviction in tech deals.
• Looks for proven founders, clear platform opportunities, and capital efficiency: he cited Zynga as a yes because the founder had a track record of creating value, the company was cash-flow positive at Series A, and the platform (Facebook) opportunity was obvious.
• Has publicly voiced skepticism about modern biotech venture economics — noting FDA/drug-development timelines can be incompatible with a 10-year fund cycle — which shapes Avalon's preference for capital-efficient, milestone-driven company construction.
• Personal north star for founders: "Just do what you find interesting and fun. Be challenged every day, and don't do what is expected of you."